ONYX

Onyx Biotec Limited

Listed company · ISIN INE0WVU01018 · NSE ST · FV ₹10
Last price
₹36
-1.37%today
What this company does

Onyx Biotec Limited is a listed company. It booked ₹69 cr of revenue in its latest year (FY26) and kept -0.3% of sales as profit.

43out of 100
Equitytale Health Score
Strained

Healthier than 43% of listed companies we score, on the 5 of 6 measures we could read for it. Each measure is ranked against the 2,387–2,932 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
42

At close. Not part of the score.

Profitability & returns24

How much profit it earns on the money it employs

Balance sheet31

How much it owes, and whether earnings cover the interest

Cash quality34

Whether reported profit actually arrives as cash

Valuation59

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
Some things to watch
Strengths
✓ Promoters hold 42%
✓ No promoter shares pledged
Watch-outs
! Currently loss-making
! Thin -0.3% net margin
! Low -0.6% return on equity

What if I invest in ONYX?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest full year + price
₹36▼ -1.37%
latest close · 2026-10-28
52-wk low ₹3563 sessions so far52-wk high ₹50
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/B ratio1.75Moderate
Below bookModerateHigh
EV / EBITDA96.7High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity-0.6%Loss
WeakFairStrong ▸15%
Return on capital1.3%Weak
WeakFairStrong
Net margin-0.3%Loss
ThinDecentStrong
EBITDA margin1.1%Thin
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.41Comfortable
LowModerateHigh ▸1
Interest cover0.7×Risky
RiskyOkayStrong ▸5×
Current ratio1.58Healthy
Tight ◂1HealthyAmple
More figures
Market cap
₹65 cr
Book value
₹21
EPS
₹-0.12
latest full year
Net debt
₹11 cr
owes more than its cash
Enterprise value
₹76 cr
EBITDA
₹79 L
latest full year
EBIT
₹79 L
latest full year
Operating margin
1.1%
Return on assets
-0.2%
Earnings yield
—
P/S
0.94
Sales / share
₹38.3
Tax rate
—
Face value
₹10
Shares
1.8 cr
Working capital
₹19 cr
Current assets
₹51 cr
Current liabilities
₹33 cr
Delivery %
98.9%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are from the latest full-year results; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-10-28.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
One year's profit is a one-off (far above the multi-year norm), so its recurring earnings power is unclear.
Models span ₹5–₹5, midpoint ₹5

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · FY26 (consolidated)
Revenue from Operations₹69 cr
Other Income₹44.5 L
Total Income₹70 cr
Cost of Materials₹51 cr
Purchases of Stock-in-Trade₹53.7 L
Employee Benefit Expense₹9 cr
Finance Costs₹1 cr
Other Expenses₹6 cr
Total Expenses₹70 cr
Profit before Tax₹-42.2 L
Tax Expense₹-20.7 L
Net Profit₹-21.4 L
Net margin on total income-0.3%
Where the money goes · FY26
% of total spend
Materials + stock-in-trade₹52 cr73.4%
Employee benefit expense₹9 cr12.2%
Finance costs₹1 cr1.7%
Other expenses₹9 cr12.6%
Total income ₹70 cr

The company made a net loss of ₹21.4 L this year — income covered only ₹99 of every ₹100 it spent on costs and tax.

Annual results · consolidated (₹ cr)
MetricFY25FY26
Revenue62 cr69 cr
Total income63 cr70 cr
Expenses57 cr70 cr
Profit before tax6 cr-42.2 L
Tax2 cr-20.7 L
Net profit (owners' share)5 cr-21.4 L
Net margin (owners' share, on revenue)8.0%-0.3%
EPS (₹)3.30-0.12
YoY (latest year): total income +10.8% · net profit —
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹95 cr
Shareholder equity
₹37 cr
parent shareholders
Total debt
₹15 cr
Cash
₹4 cr
Cash flow · H1 FY25
Operating
₹1 cr
Investing
₹1 cr
Financing
₹-2 cr
Who owns it · 2026-09-30
No pledge
Promoter
41.7%
FII / Foreign
0.2%
DII / Domestic
2.4%
Retail / others
55.6%
Promoter stake down 23.4% over the last 5 quarters.
Smart-money activity
Bulk / block deals
BoughtTUSHAR KINKER · NSE1.22 L @ ₹3816 Sep 26
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 28 Sep 2026
See the official result
1
To consider and adopt the: Audited Annual Financial Statements of the Company for the financial year ended 31st March, 2026 and the Reports of the Board of Directors and the Auditors’ thereon; and
Backed by 100% of shareholders other than promotersneeded 50%
52.84 L votes for, 0 against
2
To appoint a Director in place of Mr. Harsh Mahajan (DIN: 09793917), who retires by rotation and being eligible offers himself for re-appointment.
Backed by 100% of shareholders other than promotersneeded 50%
52.84 L votes for, 0 against
3
Ratification of remuneration to Cost Auditors of the Company.
Backed by 100% of shareholders other than promotersneeded 50%
52.84 L votes for, 0 against
4
Change in designation of Mr. Naresh Kumar (DIN: 02214241) from Whole-Time Director to Managing Director of the Company.
Backed by 100% of shareholders other than promotersneeded 75%
52.84 L votes for, 0 against

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 46 named members
owning 41.7% between them · as of 2026-09-30
NARESH KUMAR23.97%
FATEH PAL SINGH11.57%
SANJAY JAIN6.18%
Riya Chadha0.02%
Anita Mahajanno shares
Anu Soodno shares
Arun Kumarno shares
Ashok Balano shares

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹25 cr raised in Nov 2024 by selling shares to the public

As of Mar 2026, the company says it has spent 92% of what it set aside, leaving ₹2 cr still to be spent.

Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use
71%
₹4 cr of ₹6 cr
Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections
74%
₹91.6 L of ₹1 cr
Prepayment or repayment of all or a portion of certain loans availed by our Company
100%
₹12 cr of ₹12 cr
General corporate purposes
originally ₹6 cr
budget changed
99%
₹6 cr of ₹6 cr
Spent by quarter: 71% → 79% → 92% (to Mar 2026)

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.